This is a multi-center, first-in-human, open-label, Phase 1/2A dose-escalation study in which eligible patients with metastatic castration-resistant prostate carcinoma (mCRPC) will receive oral doses of TRC253. The estimated completion date is September 2018.
The purpose of this study is to evaluate the potential mechanism of action and the safety of GET73, a new drug under development for the reduction of craving and drinking in alcohol dependent individuals. The study involves five to six visits over a three to four week period, including one to two assessment visits and two visits during which participants will be assigned to take, in a double-blinded fashion, both GET73 and a placebo (two visits during each condition). During three of these visits, participants will undergo a one-hour MRI scan. Compensation is available for qualified participants.
This study is for patients who have been diagnosed with an advanced form of cancer and your disease improved or remained unchanged after receiving PD-1/ PD-L1 Checkpoint Inhibitor Therapy. The investigational drug in this study is called ALT-803. Participants will receive the study drug ALT-803 in combination with an approved PD-1/PD-L1 Checkpoint Inhibitor Therapy (Pembrolizumab, Nivolumab, Atezolizumab, or Avelumab). The purpose of this research study is to test the effectiveness of the study drug, ALT-803, in combination with pembrolizumab, nivolumab, atezolizumab, or avelumab in with advanced forms of cancer that initially had improvement or no change in disease after receiving checkpoint inhibitor therapy and who now have disease worsening. Participation in this study should take approximately 24 months.
This is a first-in-humans gene therapy study for subjects diagnosed with severe hemophilia A. A one time infusion of the gene therapy product (BAX888) will be given with the hope of eliminating or reducing the need for prophylactic and/or on-demand use of FVIII concentrate therapy. Up to 10 subjects will be enrolled study-wide with up to two subjects enrolled at MUSC. This study will require weekly visits to the study clinic after initial infusion for the first 15 weeks followed by monthly visits for the first year. Compensation will be provided.
This study is for patients that have been diagnosed with a type of cancer called Acute Myeloid Leukemia (AML). The investigational drug in this study is ONO-7475. The purpose of this study is to see whether ONO-7475 slows down the growth of cells that cause cancers like leukemias such as AML. The estimated duration of study participation in Part A is 6 months. You can continue in the study as long as you are gaining benefit from the study treatment.
This double-blinded placebo-controlled research study is being done to test the effectiveness, safety, and tolerability of the experimental drug JBT-101 in patients with systemic lupus erythematosus (SLE). We will see if JBT-101 taken by mouth stops inflammation and how well JBT-101 is tolerated. The study will evaluate whether JBT-101 will decrease the pain associated with active arthritis or tendonitis in SLE subjects. JBT-101 is manufactured entirely from chemicals and its structure is similar to the end product of a chemical in marijuana. This drug was designed to have the known anti-inflammatory properties of marijuana without the effects on brain function and mood.
The primary objective of the trial is to assess the ability of hydroxychloroquine to prevent the development of SLE in persons at risk for the disease. Subjects will be assigned to one of two groups: one with receive oral hydroxychloroquine, and one will receive oral placebo. The study lasts for about two years, with visits being once every 3 months, for a total of 12 visits. Two of those visits will be with an ophthalmologist to monitor eye health. At each visit, the study team will monitor your symptoms and health.
This is a phase 1b/2, open-label, multicenter trial designed to look at the safety and efficacy of a study drug called SD 101 when injected into a tumor and used in combination with intravenous (IV) pembrolizumab in subjects with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The Medical University of South Carolina will only participate in phase 2 of this study and will include up to 10 subjects. Participation in this study will include up to 40 visits to the research center over approximately 110 weeks.
This study is for patients that have been diagnosed with Relapsed/Refractory Acute Myeloid Leukemia (AML) or in Newly Diagnosed Older (?65 Years) AML Subjects. The investigational drug in this study is Azacitidine (AZA) and Pembroluzimab (KEYTRUDA). The purpose of this study is to determine the safety, tolerability and efficacy of Azacitidine (AZA) in combination with Pembrolizumab (also known as KEYTRUDA TM) in relapsed and refractory acute myeloid leukemia (AML) subjects, and also in older (?65 years) newly diagnosed AML subjects who are not candidates for intensive induction chemotherapy. Participants can expect to be in this study for up to 2 1/2 years.
This study is being done to evaluate an experimental treatment for people with Cystic Fibrosis who have a bacterial infection in their lungs. Subjects will be randomized (selected by chance) to either be treated with an investigational inhaled gaseous drug (in 99.5% nitrogen) that is mixed with room air or breathe 100% nitrogen that is mixed with room air. If you are randomized to the investigational treatment, we are asking you to breathe in a gas called "nitric oxide". Participation in the study will take about 43 days